Jacob Schachter

  • 7694 Citations
  • 32 h-Index
1986 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 12 Similar Profiles
Melanoma Medicine & Life Sciences
Tumor-Infiltrating Lymphocytes Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Adoptive Transfer Medicine & Life Sciences
Cell- and Tissue-Based Therapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1986 2019

An open-label, multicentre safety study of vemurafenib in patients with BRAF V600 -mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies

Early and late hematologic toxicity following CD19 CAR-T cells

Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A. & Jacoby, E., Jan 1 2019, In : Bone marrow transplantation.

Research output: Contribution to journalArticle

Neurotoxicity Syndromes
Antigen Receptors

Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients

Ben-Betzalel, G., Steinberg-Silman, Y., Stoff, R., Asher, N., Shapira-Frommer, R., Schachter, J. & Markel, G., Feb 1 2019, In : European Journal of Cancer. 108, p. 61-68 8 p.

Research output: Contribution to journalArticle

Disease-Free Survival

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 othersDummer, R., Kirkwood, J. M. & Long, G. V., May 1 2019, In : The lancet oncology. 20, 5, p. 701-710 10 p.

Research output: Contribution to journalArticle

Quality of Life

Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors

Asher, N., Marom, E. M., Ben-Betzalel, G., Baruch, E. N., Steinberg-Silman, Y., Schachter, J., Shapira-Frommer, R. & Markel, G., May 1 2019, In : Oncologist. 24, 5, p. 640-647 8 p.

Research output: Contribution to journalArticle